eligibility_summary
Eligible: histologically confirmed prostate adenocarcinoma (NE features allowed, not small cell, carcinoid, mixed NE, or large-cell NE), measurable/evaluable per PCWG3, prior orchiectomy or ongoing/continued GnRH-based ADT for Parts 1/2A/2B, ECOG 0–1. Exclude: active autoimmune disease in past 12 months needing systemic immunosuppression, within 6 months MI, unstable angina, significant ventricular arrhythmias, CHF NYHA II–IV, TIA, or stroke.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1 combo immunotherapy for advanced prostate cancer testing two T‑cell–engaging bispecific antibodies: 1) JNJ‑87189401, a PSMA×CD28 costimulatory bispecific antibody, 2) JNJ‑78278343 (pasritamig), a KLK2×CD3 T‑cell–redirecting bispecific antibody. Mechanisms: Pasritamig binds KLK2 on prostate tumor cells and CD3 on T cells to trigger TCR-mediated cytotoxicity. JNJ‑87189401 binds PSMA on tumor cells and CD28 on T cells to deliver costimulatory signals, enhancing activation in PSMA+ settings. Targets/pathways: PSMA+ and KLK2+ prostate cancer cells, T cells via CD3/TCR and CD28 costimulation, promoting immune synapse formation and tumor cell lysis.